Chair to Seek Re-Election; Director Nominations

16 JUNE 2025


CHAIR TO SEEK RE-ELECTION; DIRECTOR NOMINATIONS
DUNEDIN, New Zealand – Pacific Edge (NZX, ASX: PEB) today advises Chairman Chris
Gallaher has accepted an invitation by the company’s Directors to seek re-election to the Board
at the company’s Annual Shareholders’ Meeting (ASM) to be held on Wednesday 6 August
2025 starting at 1.00pm in Auckland.
Pacific Edge’s Directors extended the invitation because they believe shareholders’ best
interests are served with the continuity and stability of Mr Gallaher’s leadership while the
company continues to navigate the loss of Medicare coverage for Cxbladder products.
In September 2024 Mr Gallaher signaled his intention to step down this year (2025). He is also
due to retire from the Board by rotation at the ASM in accordance with NZX Listing Rule 2.7.1.
but will now be standing for re-election. Independent Directors Sarah Park and Tony Barclay,
who are also due to retire by rotation in accordance with NZX Listing Rule 2.7.1, have indicated
they will also stand for re-election.
Mr Gallaher said: “The inclusion of Cxbladder Triage in the American Urological Association’s
new microhematuria guideline has allowed Pacific Edge to view the Local Coverage
Determination
1
that ended Medicare coverage of our tests through a different lens. As we move
through the process to seek re-coverage, I am happy to continue as Chairman to ensure we
have Board stability and continuity.”
DIRECTOR NOMINATIONS
For the purposes of Listing Rule 2.3.2, Pacific Edge meanwhile advises that the closing date
for Director nominations is Tuesday 1 July 2025.
All nominations must be received by 4.00pm on the closing date. Nominations may only be
made by a shareholder entitled to attend and vote at the Annual Shareholder Meeting and must
be accompanied by a consent in writing by the nominated person.
Nominations should be either emailed to investors@pacificedge.co.nz or addressed to:
Director Nominations
Pacific Edge Limited
PO Box 56
Dunedin 9016
New Zealand
Further details, including proxy voting forms and details of resolutions, will be provided in the
Notice of Meeting, which will be sent to shareholders prior to the meeting.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
For more information:

1
The Genetic Tests for Oncology (Specific Tests) (L39365) Local Coverage Determination was finalized by Novitas,
the Medicare Administrative Contractor with responsibility for Pacific Edge’s laboratory, in January 2025 and it
became effective in April 2025.

2

Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: +64 22 032 1263
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with microhematuria and those being monitored for
recurrent disease. The tests help improve the overall patient experience, while prioritizing time
and clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
25 peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.